Life Biosciences share glaucoma study updates for its cellular reprogramming drug
The company reported interim Phase 1 observations in three participants; the small, early safety study does not establish efficacy.
TL;DR
- Life Biosciences announced interim Phase 1 data for ER-100, an investigational treatment being studied in optic neuropathies.
- The update covered three participants with open-angle glaucoma and described safety observations and early visual-function measures.
- The study is ongoing, and the company-reported findings are preliminary rather than evidence of established benefit.
Life Biosciences said it presented interim data from its Phase 1 study of ER-100, an investigational cellular-reprogramming treatment for optic neuropathies. The company said the update covered three participants with open-angle glaucoma. [1, 2] [1] [2]
The company described the treatment as an experimental gene therapy and reported that it had not observed dose-limiting toxicities at the time of the update. It also described early visual-function observations in two participants; these are company-reported interim findings, not a controlled efficacy result. [1, 2] [1] [2]
STAT's coverage places the presentation within the company's clinical-development program, while the company's release provides its own account of the data. The trial remains in Phase 1, whose primary purpose is to assess safety and tolerability. [1, 2] [1] [2]
The number of participants is very small, follow-up is ongoing and the update does not establish whether any observed change is attributable to treatment. Larger, controlled studies and fuller reporting would be needed to assess efficacy and durability. [1, 2] [1] [2]
Why it matters
The update is an early test of whether partial cellular reprogramming can be studied in people with optic nerve disease. For the biotech sector, the milestone is entry into human testing; the available evidence remains too preliminary to support claims of clinical benefit.
Editor's note
Company-reported interim findings from three participants; no clinical benefit is established. No medical advice included.